News Releases

Printer friendly version

PROTOX ANOUNCES ADDITION TO MANAGEMENT TEAM

Vancouver, British Columbia, February 9, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) today announced that Dr. James Beesley will join the company as Director of Investor Relations, as Anthony Boone concentrates on his role as Director, Corporate Communications, managing the growing demand for communications with key stakeholder audiences.

“This strategic appointment and transition further strengthens our team and allows us to capitalize on the opportunities for growth that lay ahead,” said Dr. Fahar Merchant, President and CEO. “James brings a broad range of experience in capital markets to the team and we are pleased to have him on board. Anthony’s extensive communications background will be a strong asset in helping us establish a presence among audiences critical to Protox’s future growth.”

Dr. Beesley brings to the company a body of experience, including investor relations, corporate communications and healthcare. Before joining Protox, he served as the Director of Corporate Communications and Investor Relations at Pacgen Biopharmaceuticals Corporation, which completed an initial public offering on the TSX-Venture Exchange in December, 2006. Prior to Pacgen, Dr. Beesley was an associate in a private multidisciplinary healthcare clinic in England. In this position he played a key business development role, demonstrating a solid track record of delivering strong financial gains and increasing client base. He holds a Bachelor of Science in Biology from the University of British Columbia and a Doctorate of Chiropractic from Western States Chiropractic College in Portland, Oregon.

Anthony Boone will focus on corporate communications and business development for Protox. As Director, Corporate Communications, he will support opportunities for corporate growth and development by strengthening relationships among key external stakeholder audiences, including physicians and potential partners. Mr. Boone will also oversee the company’s communications and marketing activities.

About Protox

Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin™ and PORxin™, and currently has three clinical programs in development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase I trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. Patient enrolment is underway for a Phase I clinical study into the use of PRX302 (PORxin) to treat localized prostate cancer. PRX302 has also been approved by Health Canada to commence a Phase I clinical study for the treatment of benign prostatic hyperplasia.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox’ current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information visit our website at www.protoxtherapeutics.com, or contact:

Anthony Boone
Director, Corporate Communications
Protox Therapeutics
T: 604-688-4369
C: 778-996-4369
aboone@protoxtherapeutics.com

Michael Moore
Investor Relations
The Equicom Group
T: 416-815-0700 x 241
mmoore@equicomgroup.com

James Beesley
Director, Investor Relations
Protox Therapeutics
T: 604-688-0199
jbeesley@protoxtherapeutics.com